Revision as of 04:44, 13 February 2021 edit Whywhenwhohow (talk \| contribs) Autopatrolled, Extended confirmed users, Pending changes reviewers 45,155 edits add approval ← Previous edit		Revision as of 05:12, 13 February 2021 edit undo DMacks (talk \| contribs) Edit filter managers, Autopatrolled, Administrators 181,980 edits →‎top: +image Next edit →
Line 5: \| INN = \| type = <!-- empty --> \| image = Trilaciclib.svg \| width = \| alt = Line 106: The most common side effects include fatigue; low levels of calcium, potassium and phosphate; increased levels of an enzyme called aspartate aminotransferase; headache; and infection in the lungs (pneumonia).<ref name="FDA PR" /> Trilaciclib may help protect bone marrow cells from damage caused by chemotherapy by inhibiting [[cyclin-dependent kinase]] 4/6, a type of enzyme.<ref name="FDA PR" /> Trilaciclib is the first therapy in its class and was approved for medical use in the United States in February 2021.<ref name="FDA PR"/> Chemotherapy drugs are designed to kill cancer cells but can damage normal tissues as well.<ref name="FDA PR" /> The bone marrow is particularly susceptible to chemotherapy damage.<ref name="FDA PR" /> The bone marrow makes red blood cells, white blood cells, and platelets (small fragments in the blood) that transport oxygen, fight infection, and stop bleeding.<ref name="FDA PR" /> When damaged, the bone marrow produces fewer of these cells, leading to fatigue, increased risk of infection, and bleeding, among other problems.<ref name="FDA PR" /> Trilaciclib may help protect the normal bone marrow cells from the harmful effects of chemotherapy.<ref name="FDA PR" />

Trilaciclib: Difference between revisions